All In Biotech

Drug Trial Radar · NCT03890302

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

A Phase 1, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Single and Multiple Ascending Doses of FB704A

Last checked: Nov 19, 2026Latest source record: Jul 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Mar 14, 2019

Primary completion

May 27, 2020

Study completion May 27, 2020

Sponsor

Lead sponsor
Fountain Biopharma Inc.Industry
Sponsor type
Industry
Collaborators
Oneness Biotech Co., Ltd.
First posted
Mar 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The cause of Rheumatoid Arthritis (RA) is not fully understood. However, one of the substances secreted by certain cells in the body, interleukin-6 (IL-6), is believed to play a major role in chronic inflammation that is typical in RA. This study investigates the drug FB704A, which is believed to lower the inflammation caused by IL-6. This study will be in 2 sequential parts: a single increasing dose part (Part 1) and a multiple-increasing dose part (Part 2). Subjects will receive either active or placebo drug by IV infusion. Subjects in both parts will have a short stay in the clinic at the start of the study, then will return for outpatient visits.

Conditions

  • Rheumatoid Arthritis

Interventions

  • FB704ADrug

    Administered by IV infusion

  • PlaceboDrug

    Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs) (Part 1)Time frame: Up to Day 57
  2. Incidence of Adverse Events (AEs) (Part 2)Time frame: Up to Day 99
  3. Number of participants with clinical laboratory abnormalities (Part 1)Time frame: Up to Day 57
  4. Number of participants with clinical laboratory abnormalities (Part 1)Time frame: Up to Day 99
  5. Number of participants with physical examination abnormalities (Part 1)Time frame: Up to Day 57
  6. Number of participants with physical examination abnormalities (Part 2)Time frame: Up to Day 99
  7. Number of participants with dose limiting toxicities (DLT) (Part 1)Time frame: Up to Day 57
  8. Number of participants with dose limiting toxicities (DLT) (Part 2)Time frame: Up to Day 99

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences Clinical Kansas, Inc.

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.